IP Library Granted Patent US 7,807,822
Granted Patent B2
US 7,807,822 · App. 09/121,798 · Granted Oct 5, 2010

Methods for purifying nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,822
App. No.
09/121,798
Granted
Oct 5, 2010
Kind
B2
Abstract

Methods are provided for producing highly purified compositions of nucleic acids by using a highly streamlined and readily automated process. The methods use static mixers for lysing cells and precipitating debris, followed by centrifugation and ion exchange chromatography. The process may include a purification step using tangential flow ultrafiltration. A scaleable process for producing pharmaceutical grade plasmid DNA, useful for gene therapy, is provided.

Claims (41)

1. A method for removing endotoxin from a plasmid DNA solution comprising:

a) filtering a solution comprising plasmid DNA through a series of filters including a glass fiber filter and a nylon filter;

b) contacting the solution comprising plasmid DNA with a trimethylamino ethyl (TMAE) anion exchange chromatography resin, the solution having a conductivity at which the plasmid DNA is bound to the resin; washing the resin to elute endotoxin; and eluting the plasmid DNA with a step or continuous gradient of increasing conductivity.

2. The method of claim 1 , wherein the TMAE anion exchange chromatography resin comprises a methacrylate based copolymer having a tentacle linked TMAE functional group.

3. The method of claim 1 , wherein the plasmid DNA solution is loaded on the resin in a solution having a conductivity of less than about 50 mS/cm.

4. The method of claim 3 , wherein the plasmid DNA is step eluted with a series of buffers of increasing conductivity in a range of from about 50 to about 90 mS/cm.

5. The method of claim 1 , where the plasmid DNA solution is filtered through the series of filters prior to contacting the plasmid DNA solution with the anion exchange chromatography resin.

6. The method of claim 1 , wherein the plasmid DNA solution is a clarified lysate obtained after alkaline lysis of bacterial cells comprising the plasmid DNA and removal of precipitated proteins, chromosomal DNA and cell debris.

7. The method of claim 6 , wherein the clarified lysate is further neutralized to a pH of about 7 to about 8.5.

8. The method of claim 7 , wherein the clarified lysate is further neutralized with a buffer that decreases an ionic strength of the lysate for direct loading onto the anion exchange resin.

9. The method of claim 7 , wherein the lysate is neutralized with a buffer that comprises Tris base.

10. A method for removal of endotoxin from a plasmid DNA solution comprising:

a) filtering the plasmid DNA solution through a series of filters comprising a glass fiber filter and a nylon filter;

b) loading the filtered plasmid DNA solution onto a column comprising trimethylamino ethyl (TMAE) anion exchange resin, wherein the plasmid DNA solution is loaded onto the column in a loading buffer having a conductivity below which the plasmid DNA would elute from the resin; washing the column with a buffer having a conductivity sufficient to elute endotoxin but not plasmid DNA from the resin; and eluting the plasmid DNA with a step or continuous gradient of increasing conductivity, thereby producing a solution of anion exchange purified plasmid DNA

c) filtering the solution of anion exchange purified plasmid DNA through a further series of filters comprising a glass fiber filter and a nylon filter to remove residual endotoxins.

11. The method of claim 10 , wherein the plasmid DNA solution comprises a clarified lysate obtained following alkaline lysis and precipitation using continuous flow static mixers.

12. The method of claim 11 , wherein the clarified lysate is neutralized to a pH of about 7 to about 8.5 prior to anion exchange chromatography.

13. The method of claim 12 , wherein the clarified lysate is neutralized with a buffer that deceases an ionic strength of the lysate for direct loading onto the anion exchange resin.

14. A pharmaceutical scale method for purifying plasmid DNA comprising:

a) mixing a solution of bacterial cells comprising the plasmid DNA with an alkaline lysis solution by flowing through a first static mixer to obtain a lysate;

b) contacting the lysate with a potassium acetate precipitation solution by flowing through a second static mixer, thereby forming a precipitation mixture;

c) removing a precipitate from the precipitation mixture thereby forming a clarified lysate;

d) filtering the clarified lysate through a series of filters comprising a glass filter and a nylon filter thereby forming a filtered lysate;

e) loading the filtered lysate onto a trimethylamino ethyl (TMAE) anion ion exchange chromatography resin under conditions wherein the plasmid DNA is retained on the resin, washing the resin with a buffer that removes weakly bound impurities from the resin, and eluting the plasmid DNA with a step or continuous saline gradient, thereby producing a solution of anion exchange purified plasmid DNA; and

f) filtering the solution of anion exchange purified plasmid DNA through a further a series of filters comprising at least one glass filter and at least one nylon filter to further remove residual endotoxins.

15. The method of claim 14 , further comprising a step of RNase digestion.

16. The method of claim 14 , further comprising a step of adjusting the pH and conductivity of either the precipitation mixture or the clarified lysate to a pH in the range of about 7 to about 8.5 and a conductivity of less than about 50 mS/cm prior to the filtering step wherein the filtered lysate can be directly loaded onto the anion ion exchange chromatography resin.

17. The method of claim 14 , wherein the trimethylamino ethyl (TMAE) anion ion exchange resin comprises a methacrylate based copolymer having a tentacle linked TMAE functional group.

18. The method of claim 14 , further comprising the step of purifying the plasmid DNA solution using ultrafiltration in the presence of a gel layer that is allowed to form before starting ultrafiltration.

19. The method of claim 18 , wherein the ultrafiltration unit is an open channel tangential flow ultrafiltration unit.

20. A method for purifying plasmid DNA comprising:

a) lysing the bacterial cells by alkaline lysis and precipitation through a series of continuous flow static mixers to provide a lysate;

b) clarifying the lysate and adjusting the pH and conductivity of the lysate to a pH of about 7.0 to about 8.5 and a conductivity of less than about 50 mS/cm;

c) filtering the clarified and adjusted lysate through a filter series comprising a glass filter and a nylon filter to provide a filtered lysate;

d) purifying the filtered lysate by anion exchange chromatography using a methacrylate based copolymer resin having a tentacle linked TMAE functional group to provide a purified plasmid DNA solution;

e) filtering the purified plasmid DNA solution through a further filter series comprising a glass filter and a nylon filter to reduce endotoxin levels; and

(f) optionally, ultrafiltering and diafiltering the anion exchange purified plasmid DNA through a tangential flow open channel device in the presence of a gel-layer that is formed by an initial period of recirculation.

21. The method of claim 1 , wherein the nylon filter is a N66 nylon filter.

22. The method of claim 10 , wherein the nylon filter is a N66 nylon filter.

23. The method of claim 14 , wherein the nylon filter is a N66 nylon filter.

24. The method of claim 20 , wherein the nylon filter is a N66 nylon filter.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2015
From: TRIPLEPOINT CAPITAL LLC
To: JUVARIS BIOTHERAPEUTICS, INC.
Reel/Frame 036739/0195 →
SECURITY AGREEMENT Recorded Oct 4, 2011
From: JUVARIS BIOTHERAPEUTICS, INC.
To: TRIPLEPOINT CAPITAL LLC
Reel/Frame 027015/0765 →
MERGER Recorded Oct 6, 2010
From: VALENTIS, INC.
To: URIGEN PHARMACEUTICALS, INC.
Reel/Frame 025095/0274 →
MERGER Recorded Jul 26, 1999
From: MEGABIOS CORPORATION
To: VALENTIS, INC.
Reel/Frame 010114/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 1998
From: BRIDENBAUGH, ROBERT; DANG, WARREN; BUSSEY, LEE B.
To: MEGABIOS CORPORATION
Reel/Frame 009495/0308 →
Continuity (2)
Continuation In Part 0869109000 · Aug 1, 1996
Related Publication 20020198372A1 · Dec 26, 2002